Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Relapsed or Refractory Myelodysplastic Syndrome: Overview
Myelodysplastic syndromes (MDS) are defined by ineffective hematopoiesis resulting in blood cytopenias, and clonal instability with a risk of clonal evolution to acute myeloid leukemia (AML).Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML3. The goals of therapy for patients with MDS are to reduce disease-associated symptoms and the risk of disease progression and death, thereby improving both quality and quantity of life. Some patients may have no symptoms of disease. MDS may be detected before symptoms appear, as a result of laboratory tests that were part of a routine medical examination. Treatment for myelodysplastic syndromes includes supportive care, drug therapy, and stem cell transplantation.
“Relapsed or Refractory Myelodysplastic Syndrome- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape is provided which includes the disease overview and Relapsed or Refractory Myelodysplastic Syndrome treatment guidelines. The assessment part of the report embraces, in depth Relapsed or Refractory Myelodysplastic Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed or Refractory Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Relapsed or Refractory Myelodysplastic Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Relapsed or Refractory Myelodysplastic Syndrome.
Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs Chapters
This segment of the Relapsed or Refractory Myelodysplastic Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs
CX-01: Cantex Pharmaceuticals
CX-01 is a new chemical entity derived from unfractionated heparin with very low anticoagulant activity. CX-01 targets key protein pathways important for AML blast cell migration to the bone marrow and retention of these cells in the marrow where they are protected from chemotherapy. CX-01 also binds with proteins involved in chemotherapy resistance and the delay in platelet recovery after chemotherapy. Together, these activities are understood to sensitize AML blasts to chemotherapy and improve clinical responses. These mechanisms of action support the potential for development in myelodysplastic syndrome, multiple myeloma, and lymphomas. Currently in phase 2 of clinical trials for the treatment of Myelodysplastic Syndrome.
LP-108: Newave Pharmaceuticals
Mechanism of Action: Proto-oncogene protein c-bcl-2 inhibitors. The drug is in phase 1 of clinical trials for the treatment of Relapsed or Refractory Myelodysplastic Syndrome
BTX-A51: BioTheryX
BTX-A51 appears to block a specific leukemic stem cell target (CK1-alpha) as well as super enhancer targets (CDK7/CDK9) preventing transcription of key oncogenic genes. BTX-A51 has demonstrated remarkable preclinical animal efficacy implying the eradication of AML stem cells and the potential for use in multiple malignancies. Currently in phase 1 of clinical trials for the treatment of Myelodysplastic Syndrome.
Further product details are provided in the report……..
Relapsed or Refractory Myelodysplastic Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Relapsed or Refractory Myelodysplastic Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Relapsed or Refractory Myelodysplastic Syndrome
There are approx. 5+ key companies which are developing the therapies for Relapsed or Refractory Myelodysplastic Syndrome. The companies which have their Relapsed or Refractory Myelodysplastic Syndrome drug candidates in the mid to advanced stage, i.e. Phase II include, Cantex Pharmaceuticals and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Relapsed or Refractory Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Relapsed or Refractory Myelodysplastic Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed or Refractory Myelodysplastic Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed or Refractory Myelodysplastic Syndrome drugs.
Relapsed or Refractory Myelodysplastic Syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Relapsed or Refractory Myelodysplastic Syndrome: Overview
Myelodysplastic syndromes (MDS) are defined by ineffective hematopoiesis resulting in blood cytopenias, and clonal instability with a risk of clonal evolution to acute myeloid leukemia (AML).Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML3. The goals of therapy for patients with MDS are to reduce disease-associated symptoms and the risk of disease progression and death, thereby improving both quality and quantity of life. Some patients may have no symptoms of disease. MDS may be detected before symptoms appear, as a result of laboratory tests that were part of a routine medical examination. Treatment for myelodysplastic syndromes includes supportive care, drug therapy, and stem cell transplantation.
“Relapsed or Refractory Myelodysplastic Syndrome- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape is provided which includes the disease overview and Relapsed or Refractory Myelodysplastic Syndrome treatment guidelines. The assessment part of the report embraces, in depth Relapsed or Refractory Myelodysplastic Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed or Refractory Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Relapsed or Refractory Myelodysplastic Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Relapsed or Refractory Myelodysplastic Syndrome.
Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs Chapters
This segment of the Relapsed or Refractory Myelodysplastic Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs
CX-01: Cantex Pharmaceuticals
CX-01 is a new chemical entity derived from unfractionated heparin with very low anticoagulant activity. CX-01 targets key protein pathways important for AML blast cell migration to the bone marrow and retention of these cells in the marrow where they are protected from chemotherapy. CX-01 also binds with proteins involved in chemotherapy resistance and the delay in platelet recovery after chemotherapy. Together, these activities are understood to sensitize AML blasts to chemotherapy and improve clinical responses. These mechanisms of action support the potential for development in myelodysplastic syndrome, multiple myeloma, and lymphomas. Currently in phase 2 of clinical trials for the treatment of Myelodysplastic Syndrome.
LP-108: Newave Pharmaceuticals
Mechanism of Action: Proto-oncogene protein c-bcl-2 inhibitors. The drug is in phase 1 of clinical trials for the treatment of Relapsed or Refractory Myelodysplastic Syndrome
BTX-A51: BioTheryX
BTX-A51 appears to block a specific leukemic stem cell target (CK1-alpha) as well as super enhancer targets (CDK7/CDK9) preventing transcription of key oncogenic genes. BTX-A51 has demonstrated remarkable preclinical animal efficacy implying the eradication of AML stem cells and the potential for use in multiple malignancies. Currently in phase 1 of clinical trials for the treatment of Myelodysplastic Syndrome.
Further product details are provided in the report……..
Relapsed or Refractory Myelodysplastic Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Relapsed or Refractory Myelodysplastic Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Relapsed or Refractory Myelodysplastic Syndrome
There are approx. 5+ key companies which are developing the therapies for Relapsed or Refractory Myelodysplastic Syndrome. The companies which have their Relapsed or Refractory Myelodysplastic Syndrome drug candidates in the mid to advanced stage, i.e. Phase II include, Cantex Pharmaceuticals and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Relapsed or Refractory Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Parenteral
- Molecule Type
- Small molecules
- Polymer
- Peptide
- Gene Therapy
- Monoclonal antibodies
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Relapsed or Refractory Myelodysplastic Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed or Refractory Myelodysplastic Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed or Refractory Myelodysplastic Syndrome drugs.
Relapsed or Refractory Myelodysplastic Syndrome Report Insights
- Relapsed or Refractory Myelodysplastic Syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Relapsed or Refractory Myelodysplastic Syndrome drugs?
- How many Relapsed or Refractory Myelodysplastic Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsed or Refractory Myelodysplastic Syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsed or Refractory Myelodysplastic Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Relapsed or Refractory Myelodysplastic Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cantex Pharmaceuticals
- Novartis
- Newave Pharmaceuticals
- BioTheryX
- Agios Pharmaceuticals
- CX-01
- BTX-A51
- Ruxolitinib
- AG-120
- LP-108
Introduction
Executive Summary
Relapsed or Refractory Myelodysplastic Syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Relapsed or Refractory Myelodysplastic Syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Relapsed or Refractory Myelodysplastic Syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Relapsed or Refractory Myelodysplastic Syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AG-120: Agios Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
CX-01: Cantex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early-Stage Products (Phase I)
Comparative Analysis
BTX A51: BioTheryX
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Relapsed or Refractory Myelodysplastic Syndrome Key Companies
Relapsed or Refractory Myelodysplastic Syndrome Key Products
Relapsed or Refractory Myelodysplastic Syndrome- Unmet Needs
Relapsed or Refractory Myelodysplastic Syndrome- Market Drivers and Barriers
Relapsed or Refractory Myelodysplastic Syndrome- Future Perspectives and Conclusion
Relapsed or Refractory Myelodysplastic Syndrome Analyst Views
Relapsed or Refractory Myelodysplastic Syndrome Key Companies
Appendix
Executive Summary
Relapsed or Refractory Myelodysplastic Syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Relapsed or Refractory Myelodysplastic Syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Relapsed or Refractory Myelodysplastic Syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Relapsed or Refractory Myelodysplastic Syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AG-120: Agios Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
CX-01: Cantex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early-Stage Products (Phase I)
Comparative Analysis
BTX A51: BioTheryX
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Relapsed or Refractory Myelodysplastic Syndrome Key Companies
Relapsed or Refractory Myelodysplastic Syndrome Key Products
Relapsed or Refractory Myelodysplastic Syndrome- Unmet Needs
Relapsed or Refractory Myelodysplastic Syndrome- Market Drivers and Barriers
Relapsed or Refractory Myelodysplastic Syndrome- Future Perspectives and Conclusion
Relapsed or Refractory Myelodysplastic Syndrome Analyst Views
Relapsed or Refractory Myelodysplastic Syndrome Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Relapsed or Refractory Myelodysplastic Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Relapsed or Refractory Myelodysplastic Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Relapsed or Refractory Myelodysplastic Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Relapsed or Refractory Myelodysplastic Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
